Synairgen Supercharges R&D With $100m Financing
To Support COVID-19 Study Of Inhaled Beta-Interferon
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
